Who Paid My Doc
Victor Vergara Abreu
Humacao, PR Medical Doctor
NPI 1558312389 CMS profile 252202
Ave Font Martelo 355, Hospital Ryders, Humacao, PR 00791
General payments
$13,093
Research payments
$3,057
Ownership & investment interest
$0
Research they led as principal investigator
$197,583
Through program year 2025, Victor Vergara Abreu of Humacao, PR is reported in the CMS Open Payments database as having received $13,093 across 76 general payments and $3,057 in research payments paid to them. Separately, studies naming them as principal investigator received $197,583 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $178 | 4 | |
| 2024 | General | $21 | 1 | |
| 2023 | General | $167 | 7 | |
| 2022 | General | $272 | 14 | |
| 2021 | General | $189 | 10 | |
| 2021 | Research | $770 | 1 | |
| 2020 | General | $100 | 5 | |
| 2020 | Research | $117 | 1 | |
| 2019 | General | $12,167 | 35 | |
| 2019 | Research | $2,171 | 1 |
Beside peers
- Victor Vergara Abreu
- Puerto Rico median
- Middle half of Puerto Rico
- National median
In program year 2025, general payments to Victor Vergara Abreu were reported at $178. Among 6,407 Puerto Rico profiles paid that year, the median was $138 and the middle half received between $51 and $379.
Show as a table
| Year | Victor Vergara Abreu | Puerto Rico median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $12,167 | $136 | $56–$387 | $163 |
| 2020 | $100 | $80 | $35–$213 | $114 |
| 2021 | $189 | $110 | $37–$313 | $132 |
| 2022 | $272 | $131 | $52–$362 | $149 |
| 2023 | $167 | $127 | $50–$377 | $160 |
| 2024 | $21 | $141 | $56–$375 | $164 |
| 2025 | $178 | $138 | $51–$379 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 114 drugsPart D claims
13,682
Drug cost
$2,689,956
Branded share of claims
51.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trulicity Dulaglutide | Brand | 526 | $570,422 | |
| Ozempic Semaglutide | Brand | 348 | $353,806 | |
| Farxiga Dapagliflozin Propanediol | Brand | 365 | $280,096 | |
| Jardiance Empagliflozin | Brand | 334 | $258,880 | |
| Synthroid Levothyroxine Sodium | Brand | 2,487 | $163,828 | |
| Januvia Sitagliptin Phosphate | Brand | 158 | $121,193 | |
| Janumet Xr Sitagliptin Phos/Metformin Hcl | Brand | 201 | $118,686 | |
| Janumet Sitagliptin Phos/Metformin Hcl | Brand | 94 | $73,123 | |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | Brand | 67 | $72,851 | |
| Synjardy Xr Empagliflozin/Metformin Hcl | Brand | 95 | $64,953 |
The 10 drugs with the highest cost, of 114 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 4 billing codesPaid by Medicare
$3,205
Medicare patients
33
Services billed
68
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Diabetes | 75% | |
| High blood pressure | 75% | |
| Chronic kidney disease | 55% | |
| Arthritis | 42% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
79 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.